Forbes China ESG 50
Stories
-
WuXi Biologics receives double honors at 2026 HERA for ESG reporting and environmental excellence
WuXi Biologics (2269.HK) won Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact at the ninth Hong Kong ESG Reporting Awards, becoming the only pharmaceutical company to receive a Grand Award. The company said the awards recognize its ongoing commitment to transparent ESG disclosure and measurable environmental progress across its global operations.